Skip to content

Advertisement

  • Poster presentation
  • Open Access

Significant hypophosphatemia following major cardiac surgery: incidence and consequences

  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Critical Care20048 (Suppl 1) :P266

https://doi.org/10.1186/cc2733

  • Published:

Keywords

  • Mitral Valve
  • Coronary Artery Bypass Grafting
  • Artery Bypass
  • Coronary Artery Bypass
  • Bypass Grafting

Significant hypophosphayemia (SH) may be associated with respiratory and cardiac complications but has not been targeted as a reversible cause of these complications following cardiac surgery.

Patients and methods

We prospectively studied all patients (n = 566, males 388, females 178, mean age 65.5 [11.1] years) undergoing major cardiac surgery (coronary artery bypass grafting [CABG] 75.4%; aortic valve replacement 5.1%; aortic valve replacement + CABG 5.8%; mitral valve replacement 6.8%; other 6.9%) over a 6-month period. Phosphate levels were measured preoperatively, on admission to the ICU, and on the first postoperative day. Two groups were defined according to the ICU admission level: SH, level <0.48 mmol/l; and a control group, normal range 0.8–1.45 mmol/l. Preoperative, intraoperative and postoperative data were collected in all patients. SH was treated with intravenous sodium or potassium phosphate (0.08 mmol/kg) over 6–12 hours.

Results

SH was found in 34.3% (mean level 0.29 [0.13] vs 0.84 [0.11]). Preoperative data are presented in Table 1, and the postoperative course in Table 2. The phosphate level tended to be lower in the SH group on the first postoperative day (0.6 [0.15] vs 0.81 [0.10]), suggesting inadequate repletion.

Table 1

Parameter

SH (n = 194)

Control (n = 372)

P value

Risk score

17.9 (12.1)

16.1 (10.9)

NS

Bypass (min)

117.4 (21.4)

110.5 (12.8)

NS

Cross-clamp (min)

59.1 (10.9)

55.3 (13.3)

NS

Units blood

2.2 (1.1)

1.8 (0.9)

0.05

Units platelets

6.2 (2.4)

2.1 (1.3)

0.01

Table 2

Parameter

SH (n = 194)

Control (n = 372)

P value

Ventilation (days)

2.1 (1.7)

1.1 (0.9)

0.05

Atrial fibrillation (%)

28.4

31.1

NS

ICU stay (days)

2.6 (2.9)

2.1 (2.7)

NS

Inotrope use (%)

16

10.9

0.05

Hospital stay (days)

7.8 (3.4)

5.6 (2.5)

0.05

Mortality (%)

5.2

4.6

NS

Conclusions

As SH after cardiac surgery appears to be common and associated with major morbidity, levels should be routinely monitored.

Authors’ Affiliations

(1)
Rabin Medical Center, Petah Tikva, Isarael

Copyright

© BioMed Central Ltd. 2004

Advertisement